Recent Advances in pharmacotherapy of Respiratory Disorders
Download as PPTX, PDF
0 likes75 views
Akash Agnihotri presented on mechanisms of asthma and pathophysiology of pulmonary diseases. He discussed the mechanism of asthma including inflammation and airway narrowing. He also reviewed the pathophysiology of idiopathic pulmonary fibrosis and pulmonary arterial hypertension. Finally, he listed drugs used to treat pulmonary arterial hypertension, noting their FDA approval status.
Recent Advances in pharmacotherapy of Respiratory Disorders
- 1. Presenter: Akash Agnihotri M.Sc. Medical Pharmacology AIIMS, Rishikesh
- 9. 息 Global Initiative for Asthma, www.ginasthma.orgGINA 2020, Box 3-4A
- 10. 息 Global Initiative for Asthma, www.ginasthma.orgGINA 2020, Box 3-4C
- 11. GINA 2020, ICS: Inhaled corticosteroid DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant; pMDI: pressurized metered dose inhaler (non-CFC) This is NOT a table of equivalence. These are suggested total daily doses for the low, medium and high dose treatment options with different ICS.
- 12. GINA 2020 DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant; pMDI: pressurized metered dose inhaler (non-CFC) This is NOT a table of equivalence. These are suggested total daily doses for the low, medium and high dose treatment options with different ICS.
- 13. GINA 2020 BDP: beclometasone dipropionate; DPI: dry powder inhaler; HFA: hydrofluoroalkane propellant; pMDI: pressurized metered dose inhaler (non-CFC) This is NOT a table of equivalence. These are suggested total daily doses for the low dose treatment options with different ICS.
- 34. Pathophysiology of Idiopathic pulmonary fibrosis:
- 43. Pathophysiology of Pulmonary Arterial Hypertension:
- 44. Drugs used for Pulmonary Arterial hypertension:
- 50. Thank You